PRXL2B: A Potential Drug Target for Various Diseases (G127281)

Target Name: PRXL2B

NCBI ID: G127281

PRXL2B

PRXL2B: A Potential Drug Target for Various Diseases

PRXL2B (FAM213B variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is a member of the PRXL2 family, which is known for its role in regulating lipid metabolism and inflammation.

Recent studies have identified PRXL2B as a potential drug target or biomarker for various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders.

One of the key reasons for the interest in PRXL2B is its ability to modulate the lipid profile of the body. Lipid metabolism is a critical aspect of overall health, as it plays a vital role in the delivery of oxygen and energy to the body's cells. Imbalances in lipid metabolism, such as an increase in low-density lipoprotein (LDL) cholesterol levels or a decrease in high-density lipoprotein (HDL) cholesterol levels, can increase the risk of cardiovascular disease.

PRXL2B has been shown to play a key role in regulating the levels of different types of cholesterol in the body. In addition, it has been shown to help increase the levels of HDL cholesterol, which is known to have a beneficial effect on cardiovascular health. This may help to reduce the risk of cardiovascular disease in individuals with PRXL2B-related genetic variations.

Another potential application of PRXL2B as a drug target is its role in the regulation of inflammation. Chronic inflammation is associated with a number of diseases, including heart disease and neurodegenerative disorders. PRXL2B has been shown to play a role in reducing inflammation in various tissues, including the brain and liver. This may help to protect against the development of neurodegenerative disorders.

In addition to its potential as a drug target or biomarker, PRXL2B is also of interest as a potential therapeutic agent for a number of other conditions. For example, recent studies have suggested that PRXL2B may be a useful target for treating hypoxic-ischemic injury (HIE), which is a type of injury that occurs when oxygen and blood are depleted in the brain. HIE is often caused by ischemia, or a lack of blood flow, which can result from a blockage or rupture of an blood vessel. PRXL2B has been shown to protect against HIE in animal models, and further studies are needed to determine its potential effectiveness in humans.

Overall, PRXL2B is a protein that has significant potential as a drug target or biomarker for a variety of diseases. Its ability to modulate the lipid profile and reduce inflammation may make it an attractive candidate for further study and potential therapeutic development. Further research is needed to fully understand the role of PRXL2B in various biological processes and to determine its potential as a therapeutic agent.

Protein Name: Peroxiredoxin Like 2B

Functions: Catalyzes the reduction of prostaglandin-ethanolamide H(2) (prostamide H(2)) to prostamide F(2alpha) with NADPH as proton donor. Also able to reduce prostaglandin H(2) to prostaglandin F(2alpha) (By similarity)

The "PRXL2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRXL2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets